These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 33317461)

  • 1. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
    Nojomi M; Yassin Z; Keyvani H; Makiani MJ; Roham M; Laali A; Dehghan N; Navaei M; Ranjbar M
    BMC Infect Dis; 2020 Dec; 20(1):954. PubMed ID: 33317461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
    Alavi Darazam I; Shokouhi S; Mardani M; Pourhoseingholi MA; Rabiei MM; Hatami F; Shabani M; Moradi O; Gharehbagh FJ; Irvani SSN; Amirdosara M; Hajiesmaeili M; Rezaei O; Khoshkar A; Lotfollahi L; Gachkar L; Dehbsneh HS; Khalili N; Soleymaninia A; Kusha AH; Shoushtari MT; Torabinavid P
    Int Immunopharmacol; 2021 Oct; 99():107969. PubMed ID: 34273635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
    Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
    J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
    Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
    J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
    Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
    J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
    Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
    J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.
    Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC;
    Trials; 2020 Jul; 21(1):646. PubMed ID: 32665040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
    Ader F;
    BMJ Open; 2020 Sep; 10(9):e041437. PubMed ID: 32958495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
    Lan X; Shao C; Zeng X; Wu Z; Xu Y
    Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
    Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
    Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.